RxDoctor Payments Data

Vianey Escobedo, NP

Psychiatric/Mental Health · Brownsville, TXNPI 1306487186

Payments from drug & device makers

$1,133in general payments, 2019–2025

Across 18 payments — averaging $62.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Optinose US, Inc.$418
  • Novo Nordisk$267
  • Otsuka America Pharmaceutical, Inc.$123
  • Boehringer Ingelheim$115
  • Neurocrine Biosciences, Inc.$85
  • Acadia Pharmaceuticals Inc$60
  • plus $66 from 2 others

What the payments were for

  • Food & beverage$1,133100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,133 in reported general payments places this provider in the 60th percentile of 2,724 psychiatric/mental health providers in Texas.

See all psychiatric/mental health providers in Texas

Medicare billing

Part B allowed, 2024
$24,480
Medicare patients
47
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$13,141
EliquisApixaban26$7,483
Budesonide17$3,438
Duloxetine Hcl84$2,696
CeftriaxoneCeftriaxone In Is-Osm Dextrose21$2,191
Sertraline Hcl155$1,405
Ipratropium-AlbuterolIpratropium/Albuterol Sulfate68$1,313
Levothyroxine Sodium110$1,148
Atropine Sulfate13$1,119
Furosemide148$1,037
Triamcinolone Acetonide24$867
Atorvastatin Calcium75$846
Divalproex Sodium54$834
Mirtazapine44$802
Gabapentin89$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Albuterol Sulfate$36$19411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,724 psychiatric/mental health providers in Texas.

Other psychiatric/mental health in Brownsville

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →